Biotechnology company, Prothena, has announced positive topline P1 SAD study results for PRX005, an investigational tri-epitopic antibody for the treatment of Alzheimer’s disease.
Prothena has announced FDA clearance of IND for PRX012, a subcutaneous anti-amyloid beta antibody under investigation for the treatment of Alzheimer’s disease (AD).
The race is on: Eli Lilly has begun the application for the approval of its Alzheimer's disease (AD) treatment in the US, potentially setting it up against rival Biogen's recently approved Aduhelm.
Data presented by Prothena at AAIC on two of its Alzheimer’s disease programs suggests PRX012, its next generation anti-amyloid beta (Aβ) antibody, can clear two types of Aβ plaque in brain tissue, and that its AD vaccine program can simultaneously target...